Mutations in SQSTM1 encoding p62 in amyotrophic lateral sclerosis: genetics and neuropathology

[1]  S. Kusunoki,et al.  Mutations in the gene encoding p62 in Japanese patients with amyotrophic lateral sclerosis , 2013, Neurology.

[2]  P. S. St George-Hyslop,et al.  SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis , 2012, Neurology.

[3]  A. Kakita,et al.  p62/sequestosome 1 binds to TDP‐43 in brains with frontotemporal lobar degeneration with TDP‐43 inclusions , 2012, Journal of neuroscience research.

[4]  Jacques P. Brown,et al.  Epidemiogenetic study of French families with Paget's disease of bone. , 2012, Joint, bone, spine : revue du rhumatisme.

[5]  J. Trojanowski,et al.  Distinct TDP-43 pathology in ALS patients with ataxin 2 intermediate-length polyQ expansions , 2012, Acta Neuropathologica.

[6]  V. Meininger,et al.  Phenotype difference between ALS patients with expanded repeats in C9ORF72 and patients with mutations in other ALS-related genes , 2012, Journal of Medical Genetics.

[7]  V. Meininger,et al.  Mutations in UBQLN2 are rare in French amyotrophic lateral sclerosis , 2012, Neurobiology of Aging.

[8]  John L. Robinson,et al.  Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion , 2012, Acta Neuropathologica.

[9]  T. Geetha,et al.  Sequestosome 1/p62: across diseases , 2012, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[10]  T. Hortobágyi,et al.  p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS , 2011, Acta Neuropathologica.

[11]  S. Ajroud‐Driss,et al.  SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. , 2011, Archives of neurology.

[12]  Bruce L. Miller,et al.  Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS , 2011, Neuron.

[13]  David Heckerman,et al.  A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD , 2011, Neuron.

[14]  P. Cohen,et al.  Polyubiquitin Binding to Optineurin Is Required for Optimal Activation of TANK-binding Kinase 1 and Production of Interferon β* , 2011, The Journal of Biological Chemistry.

[15]  J. Trojanowski,et al.  A harmonized classification system for FTLD-TDP pathology , 2011, Acta Neuropathologica.

[16]  S. Ralston,et al.  A point mutation in the ubiquitin-associated domain of SQSMT1 is sufficient to cause a Paget's disease-like disorder in mice. , 2011, Human molecular genetics.

[17]  V. Meininger,et al.  Screening of OPTN in French familial amyotrophic lateral sclerosis , 2011, Neurobiology of Aging.

[18]  Patrizia Sola,et al.  Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS , 2011, Neuron.

[19]  J. Trojanowski,et al.  Motor neuron disease clinically limited to the lower motor neuron is a diffuse TDP-43 proteinopathy , 2011, Acta Neuropathologica.

[20]  O. Brady,et al.  Regulation of TDP‐43 aggregation by phosphorylation andp62/SQSTM1 , 2011, Journal of neurochemistry.

[21]  J. Trojanowski,et al.  Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis , 2011, Acta Neuropathologica.

[22]  John L. Robinson,et al.  Pathological 43-kDa transactivation response DNA-binding protein in older adults with and without severe mental illness. , 2010, Archives of neurology.

[23]  V. Meininger,et al.  SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotype–phenotype correlations , 2010, Journal of Medical Genetics.

[24]  J. Mallet,et al.  Abnormal TDP-43 and FUS proteins in muscles of sporadic IBM: similarities in a TARDBP-linked ALS patient , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[25]  V. Meininger,et al.  Questioning on the role of D amino acid oxidase in familial amyotrophic lateral sclerosis , 2010, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Takeo Kato,et al.  Mutations of optineurin in amyotrophic lateral sclerosis , 2010, Nature.

[27]  William D Fraser,et al.  Genome wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget’s disease of bone , 2010, Nature Genetics.

[28]  R. Layfield,et al.  Recent advances in understanding the molecular basis of Paget disease of bone , 2009, Journal of Clinical Pathology.

[29]  Junmin Peng,et al.  Genetic inactivation of p62 leads to accumulation of hyperphosphorylated tau and neurodegeneration , 2008, Journal of neurochemistry.

[30]  P. Hartikainen,et al.  Neuropathologic Features of Frontotemporal Lobar Degeneration With Ubiquitin-Positive Inclusions Visualized With Ubiquitin-Binding Protein p62 Immunohistochemistry , 2008, Journal of neuropathology and experimental neurology.

[31]  S. Ortolani,et al.  Genetic Epidemiology of Paget’s Disease of Bone in Italy: sequestosome1/p62 Gene Mutational Test and Haplotype Analysis at 5q35 in a Large Representative Series of Sporadic and Familial Italian Cases of Paget’s Disease of Bone , 2008, Calcified Tissue International.

[32]  J. Trojanowski,et al.  Pathological TDP‐43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations , 2007, Annals of neurology.

[33]  J. Laplanche,et al.  Paget's Disease of Bone in the French Population: Novel SQSTM1 Mutations, Functional Analysis, and Genotype–Phenotype Correlations , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[34]  K. Okamoto,et al.  Immunoreactivities of p62, an ubiqutin-binding protein, in the spinal anterior horn cells of patients with amyotrophic lateral sclerosis , 2006, Journal of the Neurological Sciences.

[35]  Bruce L. Miller,et al.  Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis , 2006, Science.

[36]  S. Ralston,et al.  Loss of Ubiquitin Binding Is a Unifying Mechanism by Which Mutations of SQSTM1 Cause Paget’s Disease of Bone , 2006, Calcified Tissue International.

[37]  S. Ralston,et al.  Genetics of Paget's disease of bone. , 1998, Clinical science.

[38]  A. Pestronk,et al.  Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein , 2004, Nature Genetics.

[39]  L. Hocking,et al.  Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. , 2002, Human molecular genetics.

[40]  Jacques P. Brown,et al.  Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. , 2002, American journal of human genetics.

[41]  Chou-Chi H. Li,et al.  Valosin-containing protein is a multi-ubiquitin chain-targeting factor required in ubiquitin–proteasome degradation , 2001, Nature Cell Biology.

[42]  E. Kuusisto,et al.  Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies , 2001, Neuroreport.

[43]  M. Swash,et al.  El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[44]  E. Dennison,et al.  The Epidemiology of Paget's Disease in Britain: Is the Prevalence Decreasing? , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[45]  J. Strominger,et al.  p62, a Phosphotyrosine-independent Ligand of the SH2 Domain of p56lck, Belongs to a New Class of Ubiquitin-binding Proteins* , 1996, The Journal of Biological Chemistry.

[46]  R. Hamdy.  Clinical features and pharmacologic treatment of Paget's disease. , 1995, Endocrinology and metabolism clinics of North America.

[47]  S. Hirai,et al.  Bunina bodies in amyotrophic lateral sclerosis immunostained with rabbit anti-cystatin C serum , 1993, Neuroscience Letters.